Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 9/20 | 0.42 |
| ▸ | CA12 | O43570 | 8/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740205 | 0.86 | CYP2A6 (0.40) | CYP2A6CA2CA12PTPRCPTPN6 | |
| SCHEMBL202117 | 0.76 | CYP2A6 (0.66) | CYP2A6CA2CA12PTPRCPTPN6 | |
| SCHEMBL6406508 | 0.74 | CYP2A6 (0.50) | CYP2A6CA2CA12PTPRCPTPN6 | |
| SCHEMBL6406503 | 0.74 | CYP2A6 (0.50) | CYP2A6CA2CA12PTPRCPTPN6 | |
| SCHEMBL6736910 | 0.73 | CA2 (0.41) | CA2 | |
| SCHEMBL6378197 | 0.73 | CYP2A6 (0.47) | CYP2A6CA2CA12PTPRCPTPN6 | |
| SCHEMBL631289 | 0.73 | CYP2A6 (0.61) | CYP2A6CA2CA12PTPRCPTPN6 | |
| SCHEMBL6404068 | 0.72 | CYP2A6 (0.44) | CYP2A6CA2CA12PTPRCPTPN6 | |
| SCHEMBL6734101 | 0.72 | CA2 (0.34) | CYP2A6CA2CA12PTPRCPTPN6 | |
| SCHEMBL4057654 | 0.72 | CYP2A6 (0.51) | CYP2A6CA2CA12PTPRCPTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | disclosed |
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | US | disclosed |
| US-20030195191-A1 | N-sulfonyl hydroxamic acid derivatives as inhibitors of cd23 | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-16 | — | — | US | disclosed |
| US-20030134880-A1 | Novel cd23 inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-17 | — | — | US | disclosed |
| EP-1280800-A1 | N-SULFONYL HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF CD 23 | SMITHKLINE BEECHAM PLC (GB) | 2003-02-05 | — | — | EP | disclosed |
| EP-1265855-A1 | NOVEL CD23 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-12-18 | — | — | EP | disclosed |
| EP-1244616-A1 | (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SmithKline Beecham plc (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001085721-A1 | N-SULFONYL HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF CD 23 | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001062715-A1 | NOVEL CD23 INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001047874-A1 | (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195191-A1 | N-sulfonyl hydroxamic acid derivatives as inhibitors of cd23 | CD40, HCAR3, TNFRSF9 | CYP2A6 398/4885CA2 409/4885CA12 285/4885 |
| US-20030134880-A1 | Novel cd23 inhibitors | CD2, CD22, CD40 | CYP2A6 1907/4885CA2 1753/4885CA12 1052/4885 |
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | CD40, CD22, CD2 | CYP2A6 392/4885CA2 673/4885CA12 165/4885 |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | CYP2A6 552/4885CA2 1138/4885CA12 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.